Edwards Lifesciences Corp (NYSE:EW) has been assigned an average rating of “Buy” from the twenty-two analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $189.00.
EW has been the subject of a number of analyst reports. Zacks Investment Research lowered CGI from a “buy” rating to a “hold” rating in a report on Wednesday, June 19th. Canaccord Genuity set a $40.00 price target on Mallinckrodt and gave the stock a “buy” rating in a report on Monday, March 18th. BTIG Research began coverage on in a report on Wednesday, April 24th. They issued a “buy” rating and a $5.00 price target for the company. Morgan Stanley set a $39.00 price objective on Re/Max and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, BMO Capital Markets lifted their price objective on Alimentation Couche-Tard from C$79.00 to C$84.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd.
NYSE:EW traded down $3.58 during trading hours on Tuesday, reaching $191.45. The stock had a trading volume of 1,026,081 shares, compared to its average volume of 1,498,925. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $182.93. Edwards Lifesciences has a 12-month low of $134.53 and a 12-month high of $197.86. The firm has a market capitalization of $39.92 billion, a PE ratio of 40.73, a P/E/G ratio of 2.45 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. During the same period last year, the business posted $1.22 earnings per share. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. As a group, equities research analysts expect that Edwards Lifesciences will post 5.29 earnings per share for the current year.
In other Edwards Lifesciences news, VP Robert W.A. Sellers sold 821 shares of the firm’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $175.36, for a total transaction of $143,970.56. Following the sale, the vice president now owns 14,176 shares in the company, valued at $2,485,903.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Catherine M. Szyman sold 1,474 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $192.00, for a total value of $283,008.00. Following the sale, the vice president now owns 21,132 shares in the company, valued at approximately $4,057,344. The disclosure for this sale can be found here. Insiders have sold 164,217 shares of company stock worth $29,618,008 in the last 90 days. Company insiders own 1.63% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pinnacle Bank purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $65,000. Mackay Shields LLC increased its holdings in shares of Edwards Lifesciences by 58.8% in the fourth quarter. Mackay Shields LLC now owns 53,020 shares of the medical research company’s stock worth $8,121,000 after buying an additional 19,624 shares during the period. Cetera Advisor Networks LLC increased its holdings in shares of Edwards Lifesciences by 3.8% in the fourth quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after buying an additional 57 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $843,000. Finally, National Pension Service increased its holdings in shares of Edwards Lifesciences by 5.4% in the fourth quarter. National Pension Service now owns 226,191 shares of the medical research company’s stock worth $39,837,000 after buying an additional 11,615 shares during the period. Institutional investors and hedge funds own 82.00% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.